---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-015116"
form_type: "8-K"
ticker: null
cik: "0000922247"
company_name: "Cyclo Therapeutics, Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T22:01:10.946750+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cyclo Therapeutics receives Nasdaq delisting notice for negative equity

## Summary
- Stockholders' equity of -$438,876 as of Mar 31, 2023, below Nasdaq's $2.5M minimum.
- Company has until June 29, 2023 to submit a compliance plan to Nasdaq.
- If plan is accepted, Nasdaq may grant an extension of up to 180 days to regain compliance.
- Failure could lead to suspension or delisting, with right to a hearing.

## SEC filing metadata
- accession: 0001437749-23-015116
- form_type: 8-K
- cik: 0000922247
- company_name: Cyclo Therapeutics, Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/922247/000143774923015116/0001437749-23-015116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/922247/000143774923015116/ctdh20230518_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-015116
- JSON: https://secwatch.observer/filing/0001437749-23-015116.json
- Plain text: https://secwatch.observer/filing/0001437749-23-015116.txt

## Key facts
- Listing & Compliance Notices
  Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 15, 2023, Cyclo Therapeutics, Inc. (the “Company”), received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $(438,876) as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023, was below the minimum requirement of $2,500,000. Pursuant to Nasdaq’s Listing Rules, the Company has 45 calendar days (until June 29, 2023), to submit a plan to regain compliance with the Rule (a “Compliance Pla
  evidence_url: https://www.sec.gov/Archives/edgar/data/922247/000143774923015116/0001437749-23-015116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.